Biopharma AI
By
Can Gilead’s $260 Million AI Investment in 2025 — Backed by Strategic AI Initiatives — Accelerate Discovery, R&D, and Commercial Impact in 2026?
Global – December 31, 2025 — Gilead Sciences, Inc. expanded its commitment to artificial intelligence (AI) throughout 2025…
Can Sanofi’s $380 Million AI Investment in 2025 — Bolstered by Strategic Partnerships — Drive Breakthroughs in Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Sanofi S.A. made significant investments in artificial intelligence (AI) across discovery, clinical…
Can Roche’s $420 Million AI Investment in 2025 — Backed by Strategic AI Deals — Boost Discovery, R&D, and Commercial Advantage in 2026?
Global – December 31, 2025 — Roche Holding AG, a global leader in pharmaceuticals and diagnostics, significantly expanded…
Can Novartis’ $480 Million AI Investment in 2025 — Bolstered by Strategic AI Deals — Accelerate Discovery, R&D, and Commercial Leadership in 2026?
Global – December 31, 2025 — Novartis International AG significantly expanded its investment in artificial intelligence (AI) across…
Are AI Healthcare Tools Raising Ethical and Access Concerns?
January 26, 2026 | AI in Healthcare | Ethics, Equity & Policy Recent commentary in leading medical and…
Is “ChatGPT for Doctors” Driving OpenEvidence’s $12 B Valuation Surge?
January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion OpenEvidence, the AI platform often…
